Cardiogen
Also known as: Peptídeo miocárdico
Molecular Identifiers
Overview
Myocardial bioregulatory tripeptide developed by the Khavinson group. Regulates gene expression in cardiac tissue and supports cardiomyocyte function. Used in short cycles for cardiovascular protection and support.
AED Ala-Glu-Asp Half-life
~2-4 hours
Administration Route
Subcutaneous or intramuscular
Category
Specialized Research
Mechanism of Action
- Regulation of gene expression in myocardial tissue
- Support for cardiomyocyte function and viability
- Normalization of cardiac energy metabolism
- Modulation of oxidative stress response in the myocardium
- Bioregulatory effect on the cardiovascular system
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day subcutaneously |
| Frequency | Once daily |
| Timing | Morning or as per protocol |
| Duration | 10-20 days, cycled 2-4 times per year |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Injection site pain
- Local redness (rare)
Presentations & Preparation
Vials of Cardiogen found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Slowly inject the diluent against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on Cardiogen.
Related Peptides
Aviptadil
50-150 mcg per administration (IV or subcutaneous) · 1-3 times daily per protocol
B7-33
100-500 mcg per injection (subcutaneous) · Once daily
Bronchogen
5-10 mg per day via subcutaneous injection · Once daily
Chonluten
5-10 mg per day subcutaneously · Once daily
Crystagen
5-10 mg per day via subcutaneous injection · Once daily
Dalargin
1-2 mg per injection (subcutaneous or intramuscular) · 1-2 times daily